Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Burgoyne, Adam M
NCT03556384: Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	2	23	US	Temozolomide, TEMODAR®	Adam Burgoyne, MD, PhD	Gastrointestinal Stromal Tumors, Sdh, GIST, Cancer	06/25	06/26
ROWAN, NCT05063565 / 2021-001907-33: TheraSphere With Durvalumab and Tremelimumab for HCC	Recruiting	2	100	Europe, US	TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy	Boston Scientific Corporation, Biocompatibles UK Ltd	Hepatocellular Carcinoma	06/27	06/27
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Recruiting	2	30	US	RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq	Replimune Inc., Roche Pharma AG	Hepatocellular Carcinoma	12/27	07/28
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Recruiting	1	321	Europe, US	INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide	Inhibrx Biosciences, Inc	Colorectal Adenocarcinoma, Ewing Sarcoma	06/26	12/26
NCT06710223: Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab	Not yet recruiting	1	20	NA	SD-101, nelitolimod, Cryotherapy, Tremelimumab, Durvalumab	University of California, San Diego, TriSalus Life Sciences	Hepatocellular Carcinoma	06/27	06/27
NCT04145141: National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer	Recruiting	N/A	500	US		National Cancer Institute (NCI)	Hepatocellular Carcinoma, Liver Cancer, Cholangiocarcinoma	12/25	12/25